ReviewArchives of microbiology2025
Understanding current challenges of antibiotic resistance to find new solutions for 2050: scientific, medical and political issues.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potentiating Effect of Beauvericin on Colistin, a Last Resort Antibiotic in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Limits of a Glycine Betaine-Derived Xenobiotic as a Trojan Horse Antimicrobial.International journal of molecular sciences · 2026Article
- A Six-Step Protocol for Monitoring Antimicrobial Resistance Trends Using WHONET and R: Real-World Application and R Code Integration.Methods and protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few decades, antibiotic resistance has emerged as a major global health concern and is projected to become the leading cause of mortality worldwide by 2050. The growing human population and global warming are expected to further exacerbate this issue by increasing interactions between humans and pathogenic organisms. Unlike other studies that focus on specific aspects of antibiotic resistance, the aim of this review is to provide a comprehensive overview of this complex topic and to identify the key challenges and unanswered questions arising from heterogeneous data, the lack of scientific consensus on critical definitions, and the widespread dissemination of resistance factors. Priority pathogens identified by the World Health Organization (WHO) are presented to illustrate the clinical manifestations and impact of multidrug-resistant strains. To maintain a consistent narrative throughout the review, two WHO priority pathogens (Haemophilus influenzae and Streptococcus pneumoniae), along with a potential future priority pathogen (Vibrio vulnificus), are used as guiding examples. The bacteria priority pathogens list published by the WHO, and those for fungi, were taken as a starting point for selecting human pathogens. Publications were then selected from Web of Science, PubMed, Scopus and sites of recognized scientific institutions. To include all pathogens with antibiotic resistance, including those not considered as priority by the WHO, V. vulnificus was added because it is already monitored by many international institutions. The selected publications have all been curated to ensure scientific relevance. Molecular aspects of pathogen antibiotic resistance in terms of emergence (e.g. target mutations) and transmission are obviously important factors to consider in the antibiotic resistance issue. Nevertheless, the versatility of definitions related to antibiotic resistance, along with the lack of resources, incomplete datasets, and insufficient standardization of data processing, clearly represent urgent challenges. Furthermore, studies of certain failed public health policies have also highlighted a lack of findings. Identifying challenges linked to antibiotic resistance will enable the scientific community, whether familiar with the subject or not, to understand medical infections issues and exchange ideas more extensively in order to find new innovative pharmacological and non-pharmacological solutions for treating patients. Finally, several diagnostics and therapeutic strategies currently developed for medical applications before 2050 are discussed at the end of this review.
Indexed as
Identifiers
40442329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.